Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
24 mars 2022 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting
08 mars 2022 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it...
Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
16 févr. 2022 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
05 janv. 2022 16h01 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
Calithera to Present at the 2021 Jefferies London Healthcare Conference
12 nov. 2021 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
09 nov. 2021 16h05 HE
|
Calithera Biosciences, Inc.
-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash...
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
05 nov. 2021 07h00 HE
|
Calithera Biosciences, Inc.
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib...
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
05 nov. 2021 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the...
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
02 nov. 2021 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
01 nov. 2021 07h00 HE
|
Calithera Biosciences, Inc.
-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride--...